In a landmark moment for its oncology ambitions, GSK has
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
The agency greenlit Jideytro for patients who have been previously treated with a ROS1 kinase inhibitor for ROS1-positive…
GSK wins early FDA approval for Jideytro, a targeted treatment for adults with advanced ROS1-positive non-small cell lung cancer.
The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker…
In what GSK says represents a potential way to transform treatment for patients with certain types of rectal cancer, the…
Antibody-drug conjugates from Kelun-Biotech and Hansoh Pharma, respectively partnered with Merck & Co. and GSK, delivered…
GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — both under FDA review in 2026.
